ArticleHIV medicine2025
Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The impact of migrant-inclusive policy on Botswana's universal HIV treatment program: a retrospective analysis of the national HIV treatment program data (2016-2022).Frontiers in public health · 2026Observational
- Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.HIV medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study provides a comprehensive overview of HIV care by combining cross-sectional and longitudinal continuum of care (CoC) analyses.
methodsUsing national surveillance data 2014-2022, a five-stage cross-sectional CoC was calculated among people living with HIV (incl. undiagnosed): diagnosed, linked to care, retained in care, on antiretroviral therapy (ART) and virally suppressed. For the longitudinal CoC, cumulative incidences (CI) were calculated for each transition.
resultsThe study included 26 191 people living with HIV. By the end of 2022, an estimated 18 302 persons were living with HIV in Belgium. Of these, 92.1% were diagnosed, 90.9% linked to care, 89.2% retained in care, 87.9% on ART and 85.6% virally suppressed. One-year post-infection diagnosis rates were 38% (2014-2016), 33% (2017-2019) and 31% (2020-2022), with differences disappearing after correction for immigration timing. Time from diagnosis to care entry remained stable at 82% within 3 months. Time to ART initiation and to viral load suppression reduced substantially, with 3-month CIs rising from 69% and 71%, respectively (2014-2016), to 91% and 77% (2020-2022). Transitions between all stages of care were the fastest among Belgian men who have sex with men. People who inject drugs had the lowest CI for care entry and viral suppression. Cumulative incidences of ART initiation increased substantially for all key populations, exceeding 90% within 3 months in 2020-2022, except for non-Belgian heterosexuals (87%).
conclusionA steady improvement in the CoC places Belgium close to the joint united nations programme on HIV/AIDS 95-95-95 targets, although populations like people who inject drugs and migrants still face significant barriers to care. Timely diagnosis by supporting existing and innovative testing strategies should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.